Headlands Technologies’s Regenxbio RGNX Stock Holding History

Headlands Technologies’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,545	Closed	-$166K	–	929
2025 Q4	$166K	Buy	+11,545	New	+$144K	0.01%	605
2025 Q3	–	Sell	-13,139	Closed	-$108K	–	1138
2025 Q2	$108K	Buy	+13,139	New	+$110K	0.01%	619
2024 Q3	–	Sell	-927	Closed	-$10.8K	–	1473
2024 Q2	$10.8K	Sell	927 -2,901	-76%	-$45.2K	﹤0.01%	969
2024 Q1	$80.7K	Buy	3,828 +2,812	+277%	+$50K	0.02%	596
2023 Q4	$18.2K	Buy	+1,016	New	+$17.9K	0.01%	681
2023 Q3	–	Sell	-2,204	Closed	-$44.1K	–	1153
2023 Q2	$44.1K	Buy	+2,204	New	+$42.5K	0.01%	490

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Headlands Technologies's RGNX Position: Q1 2026 in Review

Headlands Technologies sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 11,545 shares — an estimated $166K sold.

Headlands Technologies first reported a position in RGNX in Q2 2023 and held it in 6 quarters. The position peaked at $166K in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Headlands Technologies reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
Headlands Technologies sold 11,545 Regenxbio shares in Q1 2026, an estimated $166K.
Headlands Technologies first reported a position in Regenxbio in Q2 2023 and held it in 6 quarters.
Headlands Technologies's Regenxbio position peaked at $166K in Q4 2025.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.